Engflag

Aminofilin

Quick links to important sections

Aminofilin

Aminofilin_IT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aminofilin

Aminophylline is a prescription medication primarily classified as a bronchodilator used to treat and manage reversible airway obstruction related to chronic lung diseases. The drug itself is a compound that consists of theophylline and ethylenediamine, where the ethylenediamine component is added to enhance solubility for formulation into tablets, suppositories, and intravenous solutions. Once administered, theophylline is released and is the component responsible for the therapeutic effects.

Therapeutic Role and Administration

Aminophylline is most often used as an adjunct (additional) therapy alongside inhaled beta-2 selective agonists and systemic corticosteroids, particularly during acute exacerbations of respiratory symptoms.

Its key mechanism of action, which is clinically supported by established respiratory guidelines, involves relaxing the smooth muscles surrounding the air passages (bronchial tubes) in the lungs. By relieving muscle tension, the air passages widen, making it easier to breathe and reducing symptoms like wheezing, cough, and shortness of breath. This effect is achieved through the action of theophylline, a methylxanthine derivative, which has both bronchodilatory and mild non-bronchodilator (anti-inflammatory) properties.

Common uses include the management of symptoms associated with:

  • Asthma
  • Chronic Bronchitis
  • Emphysema (as part of Chronic Obstructive Pulmonary Disease or COPD)

Due to theophylline's narrow therapeutic window—meaning the effective dose is close to the dose that causes toxicity—treatment requires careful medical supervision and regular monitoring of drug levels in the blood. Therefore, it is a prescription-only (Rx) medication.

What side effects are possible with Aminofilin?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions of Aminophylline primarily by their effect on major body systems, notably the Nervous system, Cardiac system, and Gastrointestinal tract. Many documented effects, including common occurrences like headache, nausea, tremor, and tachycardia, are often listed with a Frequency not known, meaning the incidence cannot be reliably estimated from available data. Serious adverse reactions are highlighted in official labeling due to their clinical significance.

Documented Adverse Reaction Systems and Serious Risks

Adverse reactions that may be experienced often affect the central nervous system, causing signs of excitation, such as restlessness, insomnia, and tremor. Cardiac effects include palpitations, tachycardia, and the potential for cardiac arrhythmias.

Serious adverse reactions documented in regulatory sources include seizures (convulsions), profound hypotension, and life-threatening cardiac arrest. Gastrointestinal disturbances commonly include nausea, vomiting, and abdominal pain, with the documented risk of gastrointestinal bleeding (hematemesis).

Population-Specific Safety Considerations

The frequency and severity of adverse effects are officially stated to increase significantly when the drug's concentration in the blood exceeds a defined threshold, establishing a clear link between exposure and toxicity. Official safety profiles specify the need for caution in certain populations, including older adults, where clearance may be reduced, and patients with significant hepatic (liver) impairment, which can elevate the risk of toxicity.

Overdose and Emergency Response

Overdose Manifestations

Aminophylline overdose is associated with the toxicity of its active component, theophylline, due to its narrow therapeutic index. Regulatory documents detail that initial overdose manifestations commonly include severe gastrointestinal symptoms such as nausea, persistent vomiting, and diarrhoea, alongside neurological effects like restlessness, headache, and tremor.

Severe Outcomes and Emergency Action

The officially documented risk is the potential for rapid escalation to life-threatening systemic outcomes. Severe manifestations listed in regulatory labels include central nervous system effects such as seizures and status epilepticus, and cardiovascular events like life-threatening ventricular arrhythmias and cardiac arrest. Individuals with hepatic impairment and the elderly are officially noted to be at increased risk of severe toxicity.

For any suspected overdose, government regulatory documents mandate that individuals seek immediate medical attention and contact emergency services. Immediate help is required if severe signs, such as convulsions, difficulty breathing, or collapse, are present. All subsequent doses of the medicine must be strictly withheld.

Management Profile

Official guidance describes management as strictly symptomatic and supportive, as no specific antidote is known for theophylline toxicity. Clinical management procedures often involve GI decontamination with activated charcoal and continuous monitoring of serum theophylline levels and cardiac activity (ECG). Hemodialysis may be required in severe cases to actively remove the drug.

Therapeutic Uses of Aminofilin

The therapeutic role of Aminophylline is generally used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed for respiratory distress and impaired airflow. It is used for managing symptom clusters that create noticeable physiological strain and are relevant when supportive symptom management is appropriate.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, specifically during sudden episodes when symptoms may intensify temporarily in chronic lung diseases. Aminophylline is commonly used across conditions presenting with acute episodes and periods of heightened symptoms, including Asthma, Chronic Bronchitis, and Emphysema (COPD).

“The primary benefit is supportive relief, helping to ease the physical difficulty associated with breathing problems.”

In these scenarios, the medication assists with maintaining functional stability and provides support that helps ease the overall symptom burden for patients dealing with these persistent respiratory challenges. In a specialized context, it is considered relevant for addressing the symptom clusters associated with apnea of prematurity in premature infants, where it may assist with promoting a more consistent respiratory pattern.

Quick Fact: Relief for Airway Constriction The medication supports breathing by addressing the physiological strain in the air passages, which assists with opening them and contributes to improved airflow.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

The eligibility profile for Aminofilin is strictly defined by government regulatory documents, focusing on absolute contraindications and conditional use based on age, organ function, and specific comorbidities.

Populations for Whom Use is Contraindicated

Use of Aminofilin is formally prohibited in individuals with known hypersensitivity or allergy to theophylline, ethylenediamine, or any related xanthine compounds. Some regulatory labeling also lists absolute non-eligibility for patients with acute porphyria or active peptic ulcer disease.

Conditional Eligibility (Use with Caution) Restriction Basis
Liver Disease (e.g., cirrhosis) Significantly decreased drug clearance.
Congestive Heart Failure Reduced theophylline clearance requires close supervision.
Older Adults (typically > 60 years) Increased sensitivity and reduced clearance are common.
Children Under 1 Year Classified as a restricted population due to higher susceptibility to adverse effects.
Pregnancy/Lactation Permitted only if officially determined as essential, as the drug crosses the placenta and is secreted into breast milk.

Eligibility is also affected by acute conditions, such as severe infection or fever over 102 F for prolonged periods, which can alter the drug's metabolism and clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aminophylline, through its active component theophylline, is subject to numerous officially documented drug and substance interactions, primarily affecting its clearance through hepatic metabolism. Co-administration with other xanthine derivatives is formally contraindicated by regulatory authorities due to the significant risk of systemic toxicity.

Exposure-Modifying Interactions

Many medicines alter theophylline plasma concentration by acting as enzyme inhibitors or inducers. Inhibitors, such as Cimetidine, Fluvoxamine, and certain Macrolide and Quinolone antibiotics, reduce theophylline clearance, increasing exposure and potential toxicity. Conversely, inducers like Phenytoin and Rifampicin, along with the herbal product St John's Wort, increase clearance, which can reduce the therapeutic effect.

Pharmacodynamic and Substance Interactions

Additive pharmacodynamic effects are documented with co-use of other agents. For instance, combining Aminophylline with Beta-2 Agonists, Corticosteroids, or certain Diuretics increases the risk of hypokalaemia. The effects of Adenosine are officially antagonized by theophylline. Furthermore, non-medicinal factors, including tobacco smoking and the consumption of large amounts of caffeine, are known to alter theophylline clearance or contribute to additive central nervous system stimulant effects.

Population Considerations

Interactions that reduce clearance are amplified in certain patient populations, as stated in regulatory labels. These include neonates, the elderly, and patients with pre-existing conditions that affect liver function, such as hepatic impairment or congestive heart failure.

Mechanism of Action

The mechanism of Aminophylline is driven by its active component, theophylline, which acts through two primary, non-selective molecular mechanisms to modulate enzymatic and receptor activity within the respiratory system.

Enzyme Inhibition and Airway Muscle Relaxation

Theophylline functions as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, mainly PDE3 and PDE4. This action elevates the concentration of cyclic AMP (cAMP) and cyclic GMP (cGMP) within airway smooth muscle cells. The resulting rise in these signaling molecules directly causes the muscles surrounding the bronchial tubes to relax, resulting in an increase in the caliber of the air passages (bronchodilation).

Receptor Antagonism and Pathway Modulation

The drug is also a non-selective antagonist of adenosine receptors throughout the body. By blocking these receptors, theophylline prevents adenosine from initiating signaling that promotes bronchoconstriction and the release of inflammatory chemicals. This mechanism results in the modulation of the basal activity of the airway environment, influencing the signaling pathways that mediate hyperreactivity.

Modulation of Inflammatory Gene Activity

Additionally, theophylline enhances the activity of the nuclear enzyme Histone Deacetylase 2 (HDAC2). This mechanism is involved in suppressing the transcription of pro-inflammatory genes (like those for certain cytokines). This engagement of the cellular machinery results in the modulation of inflammatory gene expression in the airways.

Dosage and Administration Information

The use of Aminophylline is strictly defined by official administration guidelines that require individualized dosing based on therapeutic drug monitoring to ensure serum concentrations of the active component, theophylline, remain within the intended range. Doses must be calculated using the patient's ideal body weight, and the regimen depends on whether the medicine is required for acute or long-term management.

Official Dosing and Administration Routes

The medicine is available for intravenous (IV) infusion for rapid effect and for oral use (tablets or syrup) for chronic maintenance. Intramuscular administration is not recommended.

Usage Parameter Regulatory Instruction
Dosing Basis Doses are titrated based on measured serum theophylline concentrations (typically 10 to 20 mu g/ mL).
IV Administration A standard IV loading dose is given over 20 to 30 minutes. The rate of infusion must not exceed 25 mg/ minute.
Oral Schedule Used for maintenance therapy, administered in divided doses every 6, 8, or 12 hours. Extended-release tablets must be swallowed whole.
Population Adjustment IV maintenance doses must be reduced for older adults and patients with hepatic impairment due to reduced clearance.

If a missed dose is noticed, official instructions advise taking it as soon as possible unless the next dose is imminent, in which case the missed dose should be skipped; patients should not double the next dose. The administration protocol requires a pre-treatment check to confirm the patient has not received a theophylline-containing product in the previous 24 hours before giving a loading dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Aminophylline

The research into aminophylline's role was studied for specific conditions characterized by fluctuating or episodic manifestations in respiratory function. The evidence available primarily comes from randomized controlled trials (RCTs) and systematic reviews, which research examined how symptoms and functional measures change over defined time intervals.

Evidence for Acute Asthma Exacerbations

Research has explored the use of intravenous aminophylline in patients—both adults and children—who are experiencing periods of heightened symptom activity known as acute asthma exacerbations. These trials were typically designed to compare the medication when added to the current standard of care versus the standard care used alone.

Systematic reviews reported that adding aminophylline to maximal standard therapy did not consistently measure significant additional changes in objective airflow measurements in adults. Findings related to airflow were inconsistent across different studies and populations. The evidence concerning major outcomes like reducing hospital admission was observed in some studies to have low certainty. The clinical heterogeneity among the available trials means that subgroup findings are uncertain, contributing to a complex overall evidence landscape.

Evidence for Acute COPD Exacerbations

The research base for acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) is more limited and relies on smaller trials and observational cohorts. Research examined the use of the drug in adults experiencing conditions involving periods of heightened symptoms.

Studies monitored outcomes capturing phases of heightened symptom activity, including patient-reported outcomes describing perceived discomfort (dyspnea scores) and changes in objective measures like arterial blood gas levels. The available data show patterns related to physiological changes in patients who did not respond well to initial standard therapy. However, the evidence relating to functional outcomes, such as the total length of hospital stay, was reported to be limited and inconsistent.

Evidence in Apnea of Prematurity

Aminophylline was studied for conditions characterized by fluctuating or episodic manifestations of breathing patterns in preterm infants. The research exploring aminophylline's role for this indication is primarily derived from comparative randomized controlled trials that explored the drug's short-term role alongside other treatments from the same drug class.

Studies monitored these responses over defined time intervals and found that the measured reduction in apnea episodes was observed to be similar between aminophylline and the comparative agent. However, research highlights that while the efficacy measures were similar, studies described differences in reported patterns related to systemic outcomes, which helps contextualize how patients reported their experience between the treatments.

Frequently Asked Questions (FAQ)

Common questions about Aminofilin (FAQ)

Q: Why is Aminofilin sometimes given in a hospital setting as an injection?

A: Aminofilin is available in a form that can be given directly into a vein (intravenous or IV infusion). The intravenous (IV) route is described in official documents for the purpose of a rapid effect, typically for management in an acute setting such as a hospital.

Q: What are the most common side effects a patient might expect when starting Aminofilin?

A: Documented effects that are common in official reports include signs of stimulation like headache, tremor (shaking), and restlessness. Gastrointestinal issues like nausea and vomiting are also listed. Official product information notes that the exact incidence or frequency of many side effects is not known from available data.

Q: Why do official sources mention a connection between a high fever and Aminofilin use?

A: Regulatory precautions note that a sustained fever of 102 F or higher is a condition that requires careful attention. This is because a high fever can decrease the clearance of the drug from the body. This change in how the body processes the medicine is why caution is advised due to the potential for elevated drug levels and toxicity.

Q: What are the signs of Aminofilin having too much effect, which might require immediate attention?

A: If the medicine concentration is too high, signs of toxicity can appear. These serious signs are highlighted in regulatory safety profiles and include persistent vomiting, an irregular or fast heartbeat, severe restlessness, and in serious cases, seizures (convulsions).

Q: How quickly does Aminofilin typically start working to relieve breathing symptoms?

A: The drug is used in two ways. The intravenous (IV) form is designed for a rapid effect and is typically administered quickly in an acute situation. The oral form is typically described for long-term maintenance and a specific time frame for the onset of effect is not consistently detailed in regulatory patient information.

Q: Why do some people refer to Theophylline when discussing Aminofilin?

A: Aminofilin (or Aminophylline) is a specific chemical compound that is made up of its main active medicine, theophylline, combined with another substance to make it soluble. Regulatory documents confirm that it is the theophylline component that is solely responsible for the therapeutic effects on the lungs.

Q: Does Aminofilin interact with alcohol?

A: Official information indicates that people with a history of alcohol abuse are noted as a population that requires closer supervision during treatment. However, specific interactions between the drug and general alcohol consumption are often not detailed in the product label.

Q: Can taking Aminofilin cause a person to feel shaky or restless?

A: Yes, official safety profiles list both restlessness and tremor (shaking hands or body movements) as documented adverse reactions. These effects are often related to the stimulating properties of the medicine on the central nervous system, as noted in regulatory sources.

Q: Are there any lung conditions besides asthma and COPD that Aminofilin is used for?

A: While the main approved uses are related to asthma and chronic obstructive pulmonary disease (COPD), official literature also references the active component, theophylline, for the management of apnea of prematurity. This use is restricted to specialized settings for treating breathing issues in preterm infants.

Q: Does Aminofilin interact with common non-prescription pain relievers or cold medicines?

A: Official interaction lists often highlight that the drug can interact with common over-the-counter medicines. For example, regulatory data indicates potential interactions with agents such as Acetaminophen (Paracetamol) and certain antihistamines found in some cold medicines.

Q: Is there a link between Aminofilin use and low potassium levels in the blood?

A: Yes, official safety information indicates that hypokalemia (abnormally low potassium levels) is a documented adverse event. The risk of this effect is noted to be higher when Aminofilin is used in combination with certain other medicines, such as beta-2 agonists or corticosteroids.

Q: Does Aminofilin help with coughing or only wheezing?

A: The mechanism of action, which involves widening the air passages, is intended to relieve a range of respiratory symptoms. Official documents state that the medicine is used to relieve symptoms that include both wheezing and cough, as well as general shortness of breath.

Q: Why do some official documents mention its use in premature infants with breathing issues?

A: Research and official documents describe the drug's use in managing apnea of prematurity (breathing pauses) in preterm infants. In this context, the active component of Aminofilin acts as a respiratory stimulant to help maintain a steady breathing pattern.

Q: Can Aminofilin affect a person's blood pressure?

A: Official safety information documents the potential for the serious adverse effect of profound hypotension (significantly low blood pressure). This is noted as a risk, especially if the medicine levels are too high or if the IV infusion rate is too fast.

Q: Are there any known interactions between Aminofilin and common prescription heart medications?

A: Official information describes known interactions with other agents that affect the heart, such as those that work similarly to Adenosine. Regulatory documents confirm that the active component antagonizes the effects of that medication.

How should Aminofilin be stored and disposed of?

Storage and Disposal of Aminophylline

Aminophylline must be stored under specific conditions mandated by official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), and keep from freezing.
Protection Store away from heat, moisture, and direct light, typically in a closed container.
Handling The injection should be visually inspected prior to use; the unused portion of the single-dose injection must be discarded.
Child Safety The medicine must be kept out of the reach of children.

Disposal Instructions

Any unused medicinal product or waste material should be disposed of in strict accordance with local requirements. Patients are advised to consult a healthcare professional regarding the proper disposal method for any outdated or no longer needed medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aminofilin found in:

A-Z Index: